Oragenics, Inc. provided shareholders with an update on its strategic and financial progress for the first quarter of 2025 on March 27, 2025. The company reported raising approximately $5 million in new funding during Q1 2025.
This funding was secured through a balanced mix of equity and debt capital, including approximately $2.6 million via ATM equity sales and $2.25 million in non-dilutive debt financing. The company also submitted a grant request to the Department of Defense.
Interim CEO Janet Huffman stated that this funding underscores the company's ability to secure capital through multiple channels. The capital is crucial for advancing the ONP-002 program and maintaining operational momentum.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.